Reduced Kidney Function Estimated by Cystatin C and Clinical Outcomes in Hypertensive Patients with Coronary Artery Disease: Association with Homocysteine and Other Cardiovascular Risk Factors (original) (raw)
Article navigation
Research Articles| May 28 2010
a1st Department of Coronary Artery Disease,
Search for other works by this author on:
bDepartment of Hypertension, and
Search for other works by this author on:
fDepartment of Nephrology, Endocrinology and Metabolic Diseases, Medical University of Silesia, Katowice, Poland
Search for other works by this author on:
bDepartment of Hypertension, and
Search for other works by this author on:
cDepartment of Heart Failure and Transplantation, Institute of Cardiology,
Search for other works by this author on:
fDepartment of Nephrology, Endocrinology and Metabolic Diseases, Medical University of Silesia, Katowice, Poland
Search for other works by this author on:
a1st Department of Coronary Artery Disease,
Search for other works by this author on:
a1st Department of Coronary Artery Disease,
Search for other works by this author on:
d2nd Department of Clinical Radiology, and
Search for other works by this author on:
a1st Department of Coronary Artery Disease,
Search for other works by this author on:
eDepartment of Pharmacognosy and Molecular Basis of Phythotherapy, Medical University of Warsaw, Warsaw, and
Search for other works by this author on:
Kidney Blood Press Res (2010) 33 (2): 139–148.
Citation
Zofia Dzielinska, Andrzej Januszewicz, Andrzej Wiecek, Aleksander Prejbisz, Tomasz Zielinski, Jerzy Chudek, Magdalena Makowiecka-Ciesla, Marcin Demkow, Pawel Tyczynski, Magdalena Januszewicz, Witold Ruzyllo, Marek Naruszewicz; Reduced Kidney Function Estimated by Cystatin C and Clinical Outcomes in Hypertensive Patients with Coronary Artery Disease: Association with Homocysteine and Other Cardiovascular Risk Factors. _Kidney Blood Press Res 1 June 2010; 33 (2): 139–148. https://doi.org/10.1159/000314812
Download citation file:
Abstract
Aims: To evaluate the association between serum cystatin C and homocysteine concentrations, cardiovascular risk factors and cardiovascular events in hypertensive patients with coronary artery disease (CAD). Methods: 260 patients with hypertension and CAD (mean age 56.9 ± 9.3) were included. During a mean 40-month follow-up the combined end-point of death from all causes, non-fatal myocardial infarction and stroke or coronary revascularization was assessed. Results: Subjects in the highest serum cystatin C quartile (>103.4 nmol/l) as compared with the lowest were older, were characterized by a higher frequency of multivessel CAD, higher levels of homocysteine (13.2 ± 5.2 vs. 11.4 ± 4.2 µmol/l; p < 0.01), fibrinogen and high-sensitivity C-reactive protein and by an increased intima-media thickness. Combined end-point occurred twice as frequently in the 4th quartile of serum cystatin C as compared with the 1st quartile (10.8 vs. 20.3%; p = 0.11). In an univariate analysis, but not in a multivariate model, cystatin C concentration predicted the combined end-point (Exp(B) = 1.096; p < 0.05). Conclusion: In hypertensive patients with CAD, serum cystatin C level was independently associated with the extent of CAD, homocysteine plasma level and traditional vascular risk factors. However, serum cystatin C concentration did not independently predict the combined end-point.
This content is only available via PDF.
© 2010 S. Karger AG, Basel
2010
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.
Sign in
Digital Version
Pay-Per-View Access
$39.00
1 Karger Article Bundle Token
$150
Rental
This article is also available for rental through DeepDyve. 